来自植物的化合物用于治疗自身主导的多囊性病
Jieting Zhang1,2, Jiaxin Chen2, Jing Xu2
1School of Medicine, Shanghai University, Shanghai, China.
Frontiers in nephrology
|September 7, 2023
概括
植物衍生化合物在减缓自身主导多囊性病 (ADPKD) 的进展方面表现有前途. 这些天然化合物可能为这种常见的遗传性病提供新的治疗策略.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 药理学 药理学是指药理学的学科.
- 自然产品化学 自然产品化学
背景情况:
- 自体主导多囊性病 (ADPKD) 是最常见的遗传性病,也是末期病的主要原因.
- 目前的治疗重点是减缓疾病进展,像托尔瓦普坦这样的化学药物显示出有效性.
- 由于其潜在的治疗益处,人们对用于ADPKD管理的天然化合物越来越感兴趣.
研究的目的:
- 审查植物化合物在治疗ADPKD中的作用和机制.
- 探索这些天然化合物的潜力,作为ADPKD的未来治疗方法.
- 要突出在临床前模型中证明有效性的特定植物衍生化合物.
主要方法:
- 对研究植物衍生化合物用于ADPKD的文献综述.
- 分析这些化合物影响囊发育的机制,包括细胞增殖和亡.
- 包括对众所周知的和新兴的植物衍生化合物和合成化合物 (如甲胺) 的研究.
主要成果:
- 已经确定了许多植物性化合物,包括saikosaponin-d,黄素,白醇和ginkgolide B,可以减缓囊的生长.
- 这些化合物通过抑制上皮细胞增殖或在囊中促进亡来发挥作用.
- 一种合成的化合物梅特福林也在减缓ADPKD进展方面表现出有效性.
结论:
- 植物衍生化合物代表了新型ADPKD治疗的有希望的途径.
- 了解这些天然化合物的作用机制可以指导未来的药物开发.
- 对这些化合物的进一步研究可能会导致ADPKD更有效和潜在的更安全的治疗方法.
相关概念视频
Chronic Kidney Disease III: Interprofessional Care
41
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
41
Chronic Kidney Disease I: Introduction
33
Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage kidney disease (ESKD). At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate...
33
Renal Drug Excretion: Tubular Secretion
215
Active tubular secretion is a robust, energy-demanding process that utilizes carrier systems to transport drugs into renal tubules. The active renal secretion systems include the organic anion transporter (OAT) for weak acids and the organic cation transporter (OCT) for weak bases. Structurally similar drugs can compete for the same transporter, potentially leading to drug accumulation and toxicity. However, this principle can be exploited therapeutically. One example is probenecid (Probalan),...
215
Antihypertensive Drugs: Potassium-Sparing Diuretics
628
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
628
Renal Corpuscle
2.5K
The glomerulus and Bowman's capsule are two essential components of the nephron, which is the functional unit of the kidney. These microscopic structures play a critical role in the process of blood filtration to produce urine.
Glomerulus: Structure and Function
The glomerulus is a tiny, intricate network of capillaries located at the beginning of the nephron. It's enveloped by the Bowman's capsule and receives its blood supply from an afferent arteriole, which divides into numerous...
Glomerulus: Structure and Function
The glomerulus is a tiny, intricate network of capillaries located at the beginning of the nephron. It's enveloped by the Bowman's capsule and receives its blood supply from an afferent arteriole, which divides into numerous...
2.5K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
199
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
199


